Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,462.00    -5.00 (-0.34%)
Bid:
1,468.00
Ask:
1,469.00
Spread: 1.00 (0.068%)
Market Cap: £3.09b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Block listing Interim Review

4 Oct 2021 09:55

RNS Number : 9028N
Hikma Pharmaceuticals Plc
04 October 2021
Β 

Hikma Pharmaceuticals PLC

Β 

Β 

Block Listing Six Monthly Return

Β 

Date: 4 October 2021

Β 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

Β 

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

SOP: 792,700 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 0 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 792,700 Ordinary Shares of 10 pence

Β 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

Β 

Β 

Block Listing Six Monthly Return

Β 

Date: 4 October 2021

Β 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

LTIP: 57,502 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

LTIP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

LTIP: 0 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

LTIP: 57,502 Ordinary Shares of 10 pence

Β 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

Β 

Block Listing Six Monthly Return

Β 

Date: 4 October 2021

Β 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("2009 MIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

2009 MIP: 136,182 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

2009 MIP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

2009 MIP: 136,182 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

2009 MIP: 0 Ordinary Shares of 10 pence

Β 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

Β 

Block Listing Six Monthly Return

Β 

Date: 4 October 2021

Β 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2018 Management Incentive Plan ("2018 MIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

2018 MIP: 1,000,000 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

2018 MIP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

2018 MIP: 226,506 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

2018 MIP: 773,494 Ordinary Shares of 10 pence

Β 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

Β 

Block Listing Six Monthly Return

Β 

Date: 4 October 2021

Β 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

EIP: 1,239,967 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

EIP: 350,000 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

EIP: 340,434 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

EIP: 1,249,533 Ordinary Shares of 10 pence

Β 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

Β 

LEI: 549300BNS685UXH4JI75

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
BLRUPGCAUUPGURC
Date   Source Headline
7th Mar 20225:12 pmRNSTransaction in Own Shares
7th Mar 20221:36 pmRNSDirector/PDMR Shareholding
4th Mar 20226:20 pmRNSTransaction in Own Shares
3rd Mar 20225:44 pmRNSTransaction in Own Shares
3rd Mar 20222:44 pmRNSDirector/PDMR Shareholding
2nd Mar 20226:18 pmRNSTransaction in Own Shares
1st Mar 20225:57 pmRNSTransaction in Own Shares
28th Feb 20226:37 pmRNSTransaction in Own Shares
28th Feb 20225:16 pmRNSDirector/PDMR Shareholding
25th Feb 20225:58 pmRNSHikma Share Buyback Programme
25th Feb 20229:37 amRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSShare Buyback Programme
24th Feb 20227:00 amRNSDirectorate Change
24th Feb 20227:00 amRNSFinal Results
23rd Feb 20229:23 amRNSHolding(s) in Company
16th Feb 202211:26 amRNSDirector/PDMR Shareholding
11th Feb 202210:17 amRNSHolding(s) in Company
8th Feb 202210:17 amRNSNotice of Results
3rd Feb 20227:00 amRNSHikma completes acquisition of Teligent
2nd Feb 202210:04 amRNSTotal Voting Rights
24th Jan 202212:45 pmRNSHolding(s) in Company
17th Jan 20227:00 amRNSAcquisition
12th Jan 20223:22 pmRNSHolding(s) in Company
10th Jan 20227:00 amRNSHikma Launches 503B Sterile Compounding Business
4th Jan 20222:55 pmRNSTotal Voting Rights
16th Dec 20211:42 pmRNSHolding(s) in Company
14th Dec 20212:34 pmRNSHolding(s) in Company
9th Dec 20217:00 amRNSRichter and Hikma sign agreement for denosumab
2nd Dec 202110:33 amRNSHolding(s) in Company
23rd Nov 20219:57 amRNSHolding(s) in Company
17th Nov 202110:35 amRNSHolding(s) in Company
4th Nov 20217:00 amRNSTrading Statement
1st Nov 20212:06 pmRNSTotal Voting Rights
4th Oct 20219:55 amRNSBlock listing Interim Review
27th Sep 20217:00 amRNSHikma acquires Custopharm
23rd Sep 20217:30 amRNSAdditional Listing
27th Aug 202112:15 pmRNSBio-Thera and Hikma announce exclusive agreement
6th Aug 20217:00 amRNSHalf-year Report
2nd Aug 20212:48 pmRNSTotal Voting Rights
19th Jul 20219:27 amRNSNotice of Results
5th Jul 20213:43 pmRNSTotal Voting Rights
2nd Jun 20211:14 pmRNSTotal Voting Rights
17th May 20214:00 pmRNSDirector/PDMR Shareholding
30th Apr 20217:00 amRNSHikma announces US FDA approval of KLOXXADO
30th Apr 20217:00 amRNSTrading Statement
26th Apr 202111:19 amRNSHolding(s) in Company
23rd Apr 20213:51 pmRNSResult of AGM
21st Apr 20217:00 amRNSHikma resumes launch of generic Advair Diskus®
13th Apr 202111:35 amRNSBlock listing Interim Review
13th Apr 20219:19 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.